CAELYX (pegylated liposomal doxorubicin) - Important Safety Information from Janssen Cilag International NV as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 01/11/2012

Problem Or Issue:
Important Safety Information communication from Janssen Cilag International NV on reintroduction of CAELYX (pegylated liposomal doxorubicin) 20 mg (2mg/ml) vials for injection.

Important Safety Information - CAELYX (pegylated liposomal doxorubicin)

CAELYX Order Process Outline – New Patient Registration

Caelyx Managed Access Programme - Re-supply form

Caelyx Managed Access Programme - Initial Patient Registration Form

« Back